Science

Corneal blindness: stem cells may provide alternative cure

G Naga Sridhar Hyderabad | Updated on March 12, 2018 Published on December 11, 2014

Sayan Basu, corneal surgeon and scientist at LV Prasad Eye Institute with James L Funderburgh (on screen), Professor of Ophthalmology at University of Pittsburg School of Medicine. PV SIVAKUMAR

lvprasad   -  Business Line

There could be an alternative to corneal transplantation to cure blindness, thanks to collaborative research findings by a research team from India and the US.

The animal studies conducted on the efficacy of using stem cells to treat scarring of whitening of cornea, the central dark portion of the eye, in curing blindness gave positive results, Sayan Basu, consultant corneal surgeon and scientist, LV Prasad Eye Institute (LEPEI), told newspersons on Thursday.

Basu is working along with James L Funderburgh, Professor of Ophthalmology at the University of Pittsburgh School of Medicine in a collaborative research project.

The results of the animal studies have been published on Thursday in the latest issue of the journal Science Translational Medicine. “We found that when the stem cells were applied to damaged corneas, they healed and became clear again within four weeks of treatment while those untreated remained clouded,” he said.

‘Long way’

However, there is still a long way to go. Phase I clinical studies involving 10 patients at LVPEI are currently underway and might take another six months to be completed.

“We still need to figure out whether the same set of desired results could be achieved in human patients and also the required dosage,” Funderburgh, speaking from the US through Skype said.

Second phase

Phase II clinical trials will have to be conducted. If all goes well, patients might be in a position to gain from this innovation after about three years.

“But, once proved, it will help treating corneal blindness in most cases at nominal cost,” Basu said. At present, the cost of corneal replacement ranges from ₹50,000 to ₹1.5 lakh. There are nearly 1.40 lakh patients in the waiting lists to receive corneas for transplantation in the country now, he added.

Published on December 11, 2014

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
null
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.